Chemistry:BMS-345541

Short description: Chemical compound

BMS-345541

Identifiers
IUPAC name 4-(2′-Aminoethyl)amino-1,8-dimethylimidazo[1,2-a]quinoxaline
CAS Number	445430-58-0 N
PubChem CID	9813758
IUPHAR/BPS	5669
ChemSpider	7989508 N
UNII	26SU0NEF5F
ChEMBL	ChEMBL249697 N
Chemical and physical data
Formula	C14H17N5
Molar mass	255.325 g·mol−1
3D model (JSmol)	Interactive image
SMILES n1c3c(n2c(cnc2c1NCCN)C)cc(cc3)C
InChI InChI=1S/C14H17N5/c1-9-3-4-11-12(7-9)19-10(2)8-17-14(19)13(18-11)16-6-5-15/h3-4,7-8H,5-6,15H2,1-2H3,(H,16,18) N Key:PSPFQEBFYXJZEV-UHFFFAOYSA-N N
NY (what is this?)  (verify)

BMS-345541, developed by Merck KGaA, is an anti-inflammatory, cell-permeable quinoxaline compound. It is an allosteric site-binding inhibitor with a primary target of IKK-2 and blocks the NF-κB-dependent transcription in mice.

It has no approvals for human/medical use or for use in clinical trials. No clinical trials mention it.